Keros Therapeutics, Inc. (KROS) Return on equity 2020–2025
Keros Therapeutics, Inc. (KROS) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
28.7%FY2025 · since FY2020: -17.3% → 28.7%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 28.7% | +61.5 pp |
| FY2024 | -32.8% | +13.3 pp |
| FY2023 | -46.1% | -8.3 pp |
| FY2022 | -37.7% | -13.6 pp |
| FY2021 | -24.2% | -6.8 pp |
| FY2020 | -17.3% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More KROS financial trends
KROS RevenueKROS Net incomeKROS Net marginKROS Gross profitKROS Gross marginKROS Operating incomeKROS Operating marginKROS Operating cash flowKROS Free cash flowKROS Capital expendituresKROS Stock buybacksKROS Dividends paidKROS Total assetsKROS Total liabilitiesKROS Shareholders’ equityKROS overview →